A Phase 2 Study of Oral MKC 1, Administered Twice Daily for 14 Consecutive Days in a 28-Day Cycle, in Patients With Unresectable or Metastatic Pancreatic Cancer Who Have Failed at Least One Prior Chemotherapy Regimen in Either the Neoadjuvant, Adjuvant, or First-line Metastatic Setting.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs MKC 1 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors EntreMed
- 06 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov record.
- 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov..